Methylene Blue Improves the Hepatopulmonary Syndrome
P. Schenk,C. Madl,Shahrzad Rezaie-Majd,S. Lehr,C. Mller
DOI: https://doi.org/10.7326/0003-4819-133-9-200011070-00012
IF: 39.2
2001-09-04
Annals of Internal Medicine
Abstract:The hepatopulmonary syndrome is the triad of liver disease, pulmonary gas exchange abnormalities leading to arterial hypoxemia, and widespread pulmonary vascular dilation (1, 2). Both acute and chronic liver diseases have been associated with the hepatopulmonary syndrome. Most commonly, the syndrome presents in patients with chronic liver diseases resulting in cirrhosis. Portal hypertension seems to be the predominant factor related to this syndrome. The hallmark of pulmonary vascular changes in the syndrome are dilated vessels at the precapillary and capillary levels and direct arteriovenous communications (1). This causes right-to-left shunting of blood flow, mismatch between ventilation and perfusion, and diffusion limitation (2). Measuring Pao 2 alone may underestimate the true degree of oxygenation abnormality because of hyperventilation, which is common in patients with cirrhosis. The alveolararterial difference for the partial pressure of oxygen (PAO2 Pao 2) is more accurate because it includes the determination of Paco 2 (which is low as a result of hyperventilation) (2). The prevailing clinical interest in the hepatopulmonary syndrome is based on its relatively high prevalence (it affects 5% to 29% of patients with end-stage liver disease [3]), high mortality rate (41% over an approximate 3-year period, despite clinically stable hepatic dysfunction [1]), and the failure of numerous medical therapies. The mechanism underlying this widespread pulmonary vasodilation is unknown. Over the past few years, increased attention has been focused on nitric oxide (NO), a powerful local vasodilator that contributes to the normally low pulmonary vascular tone. Increased endogenous NO production has been proposed as an important determinant of the hyperdynamic circulation in cirrhosis (4). The free radical NO activates the soluble guanylate cyclase in the vascular smooth muscle, increasing the level of the second messenger cyclic guanosine monophosphate, thereby causing vasorelaxation. In a case report, Pao 2 improved in a patient with the hepatopulmonary syndrome after administration of methylene blue (5), an oxidizing agent that blocks the stimulation of soluble guanylate cyclase by NO. We hypothesized that inhibition of NO-induced vasodilation by methylene blue would improve gas exchange and hemodynamic abnormalities in patients with severe hepatopulmonary syndrome. Methods Patients Our research protocol was approved by the institutional ethics committee of the University of Vienna. Written informed consent was obtained from each patient. We studied seven patients with severe hepatopulmonary syndrome (5 men, 2 women; mean age, 52 years [range, 33 to 64 years]), as defined by a Pao 2 of 60 mm Hg or less. The following strict criteria, recommended by Rodriguez-Roisin and colleagues [2], were used for diagnosis of the hepatopulmonary syndrome: 1) presence of chronic liver disease; 2) absence of intrinsic cardiopulmonary disease; 3) pulmonary gas exchange abnormalities, expressed as an increased PAO2 Pao 2; and 4) a positive contrast-enhanced echocardiogram suggesting intrapulmonary vascular dilation. Measurements and Medication Contrast-enhanced echocardiography was performed by using agitated saline, which creates a stream of microbubbles after intravenous injection (1). Under normal circumstances, these microbubbles, 60 to 90 m in diameter, opacify only the right-heart chambers because they are filtered in the pulmonary capillary bed and do not appear in the left side of the heart. In an intrapulmonary shunt, the microbubbles appear in the left-heart chambers 4 to 6 heart beats after their initial visualization in the right side of the heart. For hemodynamic measurements, a SwanGanz balloon-tipped pulmonary artery catheter (Thermodilution Venous Infusion Port Catheter, 7.5 French, Baxter Healthcare Corp., Irvine, California) was inserted through a central vein (jugular or subclavian). Hemodynamic measurements were performed by using standard techniques while the patient was in the supine position and in the resting state. Cardiac output was recorded in triplicate by thermodilution technique using iced saline, and the average was used for further statistical analysis. An arterial indwelling catheter (Arrow, Reading, Pennsylvania) was inserted in a radial artery for online measurement of arterial blood pressure and repeated blood gas analysis. All measurements were performed in the intensive care unit. Arterial and mixed venous blood gas analysis and hemodynamic measurements were recorded after 30 minutes of rest at baseline and again at 30 minutes and 1, 2, 3, 4, and 5 hours after intravenous administration of methylene blue, 3 mg/kg of body weight injected over a period of 15 minutes. In addition to these scheduled recordings, five patients who remained in the intensive care unit overnight had measurements recorded 10 hours after methylene blue injection. The primary outcome measure was Pao 2 and the secondary outcome variables were Paco 2, PAO2 Pao 2, heart rate, mean systemic arterial pressure, mean pulmonary artery pressure, central venous pressure, pulmonary capillary wedge pressure, cardiac output, systemic vascular resistance, pulmonary vascular resistance, and shunt fraction. Systemic vascular resistance and pulmonary vascular resistance were calculated according to standard formulas. Shunt fraction (VS/VT) was calculated using a standard equation: where CO2, CaO2, and CmvO2 represent the O2 content of ideal, arterial, and mixed venous blood, respectively. The O2 saturation of ideal blood was obtained from the calculated alveolar Po 2 and Pco 2 by using the Kelman subroutine (6). Baseline variables were calculated on the basis of three repeated measurements taken 10 minutes apart. Statistical Analysis A repeated-measures analysis of variance was performed by using proc glm of SAS (SAS Institute, Inc., Cary, North Carolina) to compare the differences between baseline and each of the time points (30 minutes and 1, 2, 3, 4, and 5 hours after intervention). To model the difference over time to baseline, the baseline minus the mean of baseline was included as a covariable. If no significant time effect was found, the average of the repeated differences over time was analyzed by testing the intercept of the model against zero. Because the covariable baseline minus average baseline is used in the model, this test refers to the average difference determined at the mean baseline value (where the covariable is zero). Because of missing data for two patients at 10 hours, a paired t-test to baseline was performed. A P value less than 0.05 was considered statistically significant. Results All patients presented with orthodeoxia (hypoxia worsens upon rising from the supine position to upright posture because of gravitational effects, which leads to increased blood flow to the lower-lung fields) and exertional dyspnea. The participants were nonsmokers who had normal lung function and clear chest radiographs. All patients had advanced cirrhosis (five with ChildPugh class C and two with class B) as established by clinical, biochemical, and histologic findings. The causes of cirrhosis were alcohol related in five patients, hemochromatosis in one patient, and cryptogenic in one patient. At the time of our investigation, no participant had detectable ascites, as assessed by sonography. Various degrees of esophageal varices were present in all patients, including a history of bleeding in three patients. All patients had clubbing of the digits and cutaneous spider nevi, and four patients had more than 50 nevi. All patients had elevated levels of total bilirubin (mean SD, 175 186 mol/L [10.2 10.9 mg/dL]) as well as a prolonged prothrombin time (mean, 36 10 seconds). The mean hemoglobin value was 94 18 g/L, the mean platelet count was 122 61 109 cells/L, and the mean serum creatinine concentration was 108 67 mol/L (1.2 0.76 mg/dL). At baseline, arterial blood gas analysis showed hypoxemia in all patients, with Pao 2 values between 53 and 60 mm Hg and an increased PAO2 Pao 2 (Table). The Paco 2 value was reduced in all patients because of hyperventilation (mean, 34 2.7 mm Hg [range, 29 to 37 mm Hg]). Shunt fraction was greatly elevated (41% 3.1%). At baseline, all patients showed hyperdynamic circulation with diminished pulmonary vascular resistance (58 23 dyne/sec cm 5) and systemic vascular resistance (527 144 dyne/sec cm 5), and elevated cardiac output (10.6 2.2 L/min). The effect of methylene blue administration on gas exchange and hemodynamic variables is shown in the Table. The one variable with a significant time effect was Paco 2. No other significant time effects were observed; for these variables, the P value refers to the test of the average repeated differences against zero. After methylene blue infusion, Pao 2 showed a significant average increase over time compared with baseline (P=0.006), from 58 2.5 mm Hg at baseline to 74 11.5 mm Hg 5 hours after methylene blue administration. Consistent with the increase in Pao 2, PAO2 Pao 2 decreased significantly from 49 3.3 mm Hg at baseline to 30 10.4 mm Hg at the 5-hour measurement (P=0.003). The Paco 2 value increased slightly (from 34 2.7 mm Hg at baseline to 37 4.5 mm Hg after 5 hours; P=0.007 for the time effect). Shunt fraction decreased significantly (P <0.001); the lowest mean value occurred at the 5-hour measurement (25% 4.5%). Table. Gas Exchange and Hemodynamic Responses to Short-Term Infusion of Methylene Blue In addition, mean pulmonary artery pressure increased significantly (from 20 5.2 mm Hg to 23 3.6 mm Hg; P=0.028), as did pulmonary vascular resistance (from 58 23 dyne/sec cm 5 to 115 56 dyne/sec cm 5; P=0.012). Mean systemic arterial pressure increased, but the difference was not statistically significant. Central venous pressure and pulmonary capillary wedge pressure did not change. Cardiac output decreased (from 10.6 2.2 L/min at baseline to 8.6 2.7 L/min